Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.45
NYSE:TFX's Cash-to-Debt is ranked lower than
82% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. NYSE:TFX: 0.45 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:TFX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.22 Max: 0.93
Current: 0.45
0.02
0.93
Equity-to-Asset 0.44
NYSE:TFX's Equity-to-Asset is ranked lower than
77% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. NYSE:TFX: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:TFX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.46 Max: 0.55
Current: 0.44
0.32
0.55
Debt-to-Equity 0.91
NYSE:TFX's Debt-to-Equity is ranked lower than
87% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 0.27 vs. NYSE:TFX: 0.91 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:TFX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.34  Med: 0.63 Max: 1.27
Current: 0.91
0.34
1.27
Debt-to-EBITDA 4.69
NYSE:TFX's Debt-to-EBITDA is ranked lower than
77% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. NYSE:TFX: 4.69 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:TFX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -63.25  Med: 3.28 Max: 6.4
Current: 4.69
-63.25
6.4
Interest Coverage 4.63
NYSE:TFX's Interest Coverage is ranked lower than
85% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. NYSE:TFX: 4.63 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:TFX' s Interest Coverage Range Over the Past 10 Years
Min: 2.18  Med: 3.26 Max: 5.81
Current: 4.63
2.18
5.81
Piotroski F-Score: 7
Altman Z-Score: 3.69
Beneish M-Score: -2.60
WACC vs ROIC
8.53%
10.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 16.87
NYSE:TFX's Operating Margin % is ranked higher than
83% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. NYSE:TFX: 16.87 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:TFX' s Operating Margin % Range Over the Past 10 Years
Min: -6.28  Med: 14.96 Max: 17.46
Current: 16.87
-6.28
17.46
Net Margin % 12.41
NYSE:TFX's Net Margin % is ranked higher than
81% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. NYSE:TFX: 12.41 )
Ranked among companies with meaningful Net Margin % only.
NYSE:TFX' s Net Margin % Range Over the Past 10 Years
Min: -12.25  Med: 11.46 Max: 21.66
Current: 12.41
-12.25
21.66
ROE % 11.28
NYSE:TFX's ROE % is ranked higher than
75% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. NYSE:TFX: 11.28 )
Ranked among companies with meaningful ROE % only.
NYSE:TFX' s ROE % Range Over the Past 10 Years
Min: -10.11  Med: 11.54 Max: 21.44
Current: 11.28
-10.11
21.44
ROA % 5.32
NYSE:TFX's ROA % is ranked higher than
71% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. NYSE:TFX: 5.32 )
Ranked among companies with meaningful ROA % only.
NYSE:TFX' s ROA % Range Over the Past 10 Years
Min: -4.96  Med: 5 Max: 8.55
Current: 5.32
-4.96
8.55
ROC (Joel Greenblatt) % 44.23
NYSE:TFX's ROC (Joel Greenblatt) % is ranked higher than
83% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. NYSE:TFX: 44.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:TFX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -13.25  Med: 31.91 Max: 44.23
Current: 44.23
-13.25
44.23
3-Year Revenue Growth Rate 0.30
NYSE:TFX's 3-Year Revenue Growth Rate is ranked lower than
62% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. NYSE:TFX: 0.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:TFX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -11  Med: 6.8 Max: 17.8
Current: 0.3
-11
17.8
3-Year EBITDA Growth Rate 5.60
NYSE:TFX's 3-Year EBITDA Growth Rate is ranked higher than
54% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. NYSE:TFX: 5.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:TFX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.8  Med: 8.5 Max: 16
Current: 5.6
-7.8
16
3-Year EPS without NRI Growth Rate 12.90
NYSE:TFX's 3-Year EPS without NRI Growth Rate is ranked higher than
65% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. NYSE:TFX: 12.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:TFX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -17.4  Med: 9.7 Max: 17.3
Current: 12.9
-17.4
17.3
GuruFocus has detected 5 Warning Signs with Teleflex Inc NYSE:TFX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:TFX's 30-Y Financials

Financials (Next Earnings Date: 2018-02-23)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

TFX Guru Trades in Q4 2016

Joel Greenblatt 30,267 sh (+355.42%)
Ron Baron 111,702 sh (+6.81%)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Third Avenue Management 23,007 sh (-0.41%)
Murray Stahl 4,285 sh (-2.28%)
Chuck Royce 154,200 sh (-15.18%)
» More
Q1 2017

TFX Guru Trades in Q1 2017

Steven Cohen 25,663 sh (New)
Eaton Vance Worldwide Health Sciences Fund 81,894 sh (New)
Ron Baron 116,762 sh (+4.53%)
Chuck Royce 154,200 sh (unchged)
Third Avenue Management 23,007 sh (unchged)
Joel Greenblatt Sold Out
Murray Stahl 4,220 sh (-1.52%)
» More
Q2 2017

TFX Guru Trades in Q2 2017

Steven Cohen 40,414 sh (+57.48%)
Ron Baron 117,002 sh (+0.21%)
Third Avenue Management Sold Out
Chuck Royce 148,050 sh (-3.99%)
Murray Stahl 4,045 sh (-4.15%)
Eaton Vance Worldwide Health Sciences Fund 59,329 sh (-27.55%)
» More
Q3 2017

TFX Guru Trades in Q3 2017

Jim Simons 32,000 sh (New)
Ken Fisher 48,617 sh (New)
Ron Baron 137,140 sh (+17.21%)
Eaton Vance Worldwide Health Sciences Fund 59,329 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 142,043 sh (-4.06%)
Murray Stahl 3,701 sh (-8.50%)
» More
» Details

Insider Trades

Latest Guru Trades with TFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2017-09-30 Add 17.21%0.02%$203.01 - $242.56 $ 266.5523%137,140
Ken Fisher 2017-09-30 New Buy0.02%$203.01 - $242.56 $ 266.5523%48,617
Ron Baron 2017-06-30 Add 0.21%$192.5 - $210.37 $ 266.5533%117,002
Third Avenue Management 2017-06-30 Sold Out 0.2%$192.5 - $210.37 $ 266.5533%0
Ron Baron 2017-03-31 Add 4.53%0.01%$158.86 - $197.1 $ 266.5548%116,762
Joel Greenblatt 2017-03-31 Sold Out 0.06%$158.86 - $197.1 $ 266.5548%0
Ron Baron 2016-12-31 Add 6.81%0.01%$139.41 - $169.09 $ 266.5571%111,702
Joel Greenblatt 2016-12-31 Add 355.42%0.05%$139.41 - $169.09 $ 266.5571%30,267
Third Avenue Management 2016-12-31 Reduce -0.41%$139.41 - $169.09 $ 266.5571%23,007
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:XSWX:SOON, NYSE:VAR, NAS:ABMD, ASX:COH, OCSE:WDH, XPAR:DIM, SZSE:300003, NZSE:FPH, LSE:CTEC, LSE:SN., NAS:MASI, OCSE:GN, OSTO:EKTA B, OCSE:AMBU B, NAS:IART, NAS:LIVN, NYSE:PEN, SZSE:002223, HKSE:01066, NYSE:GMED » details
Traded in other countries:TBH.Germany,
Headquarter Location:USA
Teleflex Inc designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

Teleflex is a medical technology company that operates in six segments: vascular North America; anesthesia North America; surgical North America; Europe, Middle East, and Africa, or EMEA; Asia; and OEM. The vascular segment sells catheters and other devices used to administer intravenous medications, as well as interventional access products. The anesthesia segment provides airway management and pain management products. The surgical segment sells devices used in surgical procedures, such as ligation and fascial closure systems. The EMEA and Asia segments primarily sell devices used in acute care and surgical settings. The OEM segment supplies devices and instruments to other medical-device manufacturers. Teleflex generates the majority of its revenue in the United States.

Guru Investment Theses on Teleflex Inc

Baron Funds Comments on Teleflex Inc. - Jul 25, 2016

We initiated a position in Teleflex, Inc. (NYSE:TFX), a medical device company that over the past five years has been transformed, under CEO Benson Smith’s leadership, from a diversified industrial company into a pure-play medical device company through a series of divestitures and acquisitions. Today, the company sells products used by hospitals and health care providers for critical care applications and surgical procedures. The company’s products include, among others, catheters that provide vascular access for delivery of intravenous medications, laryngeal masks for delivery of anesthesia, and surgical instruments used for minimally invasive surgery. The company’s products are used in procedures for treatment of acute or life-threatening illnesses and are therefore less susceptible to being cut during an economic downturn.



We think the company has a solid base business that should be able to grow in the mid-single digits on an organic basis driven by volume growth, new product introductions, and to a lesser extent pricing. In addition, we think the company has the potential to accelerate its organic growth through several interesting new product opportunities, including, among others, the Percuvance Surgical System, a surgical instrument for use in minimally invasive procedures. Percuvance requires a smaller incision site than traditional laparoscopic surgery, while maintaining the equivalent rigidity and strength of laparoscopic instruments. Percuvance has the potential to reduce patient trauma and minimize scarring. The company plans to pursue a full market release of the product in the third quarter of 2016. We think the product has widespread application and well over $100 million of revenue potential over the long term.



In addition, the company has several non-revenue dependent margin expansion initiatives in place, including manufacturing plant consolidation, acquisitions of distributors, and material substitution. New product launches at higher margins should also drive margin expansion. We think the combination of organic growth and margin expansion should drive low double-digit earnings growth, with potential for faster earnings growth if new products accelerate the revenue growth rate or management executes accretive acquisitions.



Baron Asset Fund second quarter shareholder letter.



Check out Ron Baron latest stock trades

Top Ranked Articles about Teleflex Inc

Report: Exploring Fundamental Drivers Behind UnitedHealth, CNA Financial, Essex Property Trust, Teleflex, International Flavors & Fragrances, and MSCI – New Horizons, Emerging Trends, and Upcoming Developments
5 Companies Hit 52-Week Highs Teleflex, Cabot Oil & Gas, Cognizant Technology, American Express, Stanley Black & Decker achieve milestones
According to GuruFocus list of 52-week highs, these stocks have reached their 52-week highs. Read more...
Teleflex Continues Rally; Stock Is Up Over 10% in Past 5 Days Shares have been rallying since a major acquistion was announced a week ago
Teleflex Inc. (NYSE:TFX) stock is up 10.56% in the past five-day period. The company's rally is driven by the announced acquisition of Neotract, reported on Sept. 5. Read more...
Eaton Vance Worldwide Health Sciences Fund Adds 4 Stocks to Portfolio Health care fund reports fourth-quarter activity
Jason Kritzer, vice president of Eaton Vance Management, invests in companies with a bottom-up, proprietary research approach. The portfolio manager of the Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) invested in four companies during the first quarter: Aetna Inc. (NYSE:AET), Humana Inc. (NYSE:HUM), Hologic Inc. (NASDAQ:HOLX) and Teleflex Inc. (NYSE:TFX) Read more...
Vascular Solutions Shareholders Approve Acquisition by Teleflex

MINNEAPOLIS, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC) announced that at the Special Meeting of Shareholders held earlier today, Vascular Solutions shareholders voted to approve the company’s proposed acquisition by Teleflex Incorporated (NYSE:NYSE:TFX). The proposal to adopt the Agreement and Plan of Merger dated December 1, 2016 was approved by shareholders owning approximately 99.2% of the shares voted at today’s special meeting.  The shares voted represent approximately 77.0% of the outstanding shares of Vascular Solutions as of the record date. In the merger, each share of Vascular Solutions common stock will be converted into the right to receive $56.00 in cash, without interest.  The transaction is expected to close on February 17, 2017, subject to customary closing conditions.  If the transaction closes on February 17, 2017, Vascular Solutions shares will cease trading following the closing of the market on February 17, 2017 and, thereafter, will no longer be listed on the Nasdaq Global Select Market. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the proposed transaction and business combination between Teleflex and Vascular Solutions, including statements regarding the anticipated timing of the transaction. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to:(i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Vascular Solutions’ business and the price of the common stock of Vascular Solutions, (ii) the failure to satisfy the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, and (iv) the outcome of any legal proceedings that may be instituted against Vascular Solutions or Teleflex related to the merger agreement or the transaction. In addition, please refer to the documents that Teleflex and Vascular Solutions have filed with the SEC on Schedule 14A and Forms 10-K, 10-Q and 8-K. These filings identify and address other important risks and uncertainties that could cause events and results to differ materially from those contained in the forward-looking statements set forth in this press release. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Vascular Solutions assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. About Teleflex Incorporated Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com. Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® - trusted brands united by a common sense of purpose. About Vascular Solutions Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures.  Since its founding in 1997, the company has launched more than 100 products that are sold to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network. For more information, please visit www.vasc.com.
Contact:
Vascular Solutions, Inc.
Phil Nalbone, VP
[email protected]
(763) 656-4371

Read more...

Ratios

vs
industry
vs
history
PE Ratio 48.72
TFX's PE Ratio is ranked lower than
69% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. TFX: 48.72 )
Ranked among companies with meaningful PE Ratio only.
TFX' s PE Ratio Range Over the Past 10 Years
Min: 4.99  Med: 24.59 Max: 48.98
Current: 48.72
4.99
48.98
Forward PE Ratio 27.86
TFX's Forward PE Ratio is ranked higher than
51% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. TFX: 27.86 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 48.20
TFX's PE Ratio without NRI is ranked lower than
70% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.81 vs. TFX: 48.20 )
Ranked among companies with meaningful PE Ratio without NRI only.
TFX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.97  Med: 27.35 Max: 64.93
Current: 48.2
13.97
64.93
Price-to-Owner-Earnings 39.90
TFX's Price-to-Owner-Earnings is ranked higher than
53% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 37.10 vs. TFX: 39.90 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TFX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.84  Med: 22.54 Max: 47.82
Current: 39.9
5.84
47.82
PB Ratio 5.06
TFX's PB Ratio is ranked lower than
65% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. TFX: 5.06 )
Ranked among companies with meaningful PB Ratio only.
TFX' s PB Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.86 Max: 5.08
Current: 5.06
1.04
5.08
PS Ratio 6.04
TFX's PS Ratio is ranked lower than
71% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. TFX: 6.04 )
Ranked among companies with meaningful PS Ratio only.
TFX' s PS Ratio Range Over the Past 10 Years
Min: 0.71  Med: 1.92 Max: 6.06
Current: 6.04
0.71
6.06
Price-to-Free-Cash-Flow 34.89
TFX's Price-to-Free-Cash-Flow is ranked lower than
54% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 28.08 vs. TFX: 34.89 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TFX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.92  Med: 20.71 Max: 51.5
Current: 34.89
5.92
51.5
Price-to-Operating-Cash-Flow 29.09
TFX's Price-to-Operating-Cash-Flow is ranked lower than
64% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. TFX: 29.09 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TFX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.23  Med: 16.3 Max: 29.23
Current: 29.09
5.23
29.23
EV-to-EBIT 38.54
TFX's EV-to-EBIT is ranked lower than
72% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. TFX: 38.54 )
Ranked among companies with meaningful EV-to-EBIT only.
TFX' s EV-to-EBIT Range Over the Past 10 Years
Min: -40.1  Med: 18.4 Max: 39.7
Current: 38.54
-40.1
39.7
EV-to-EBITDA 27.58
TFX's EV-to-EBITDA is ranked lower than
72% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. TFX: 27.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
TFX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -371.3  Med: 13.15 Max: 3794.7
Current: 27.58
-371.3
3794.7
EV-to-Revenue 6.42
TFX's EV-to-Revenue is ranked lower than
70% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. TFX: 6.42 )
Ranked among companies with meaningful EV-to-Revenue only.
TFX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4  Med: 2.2 Max: 6.6
Current: 6.42
1.4
6.6
Shiller PE Ratio 57.82
TFX's Shiller PE Ratio is ranked lower than
60% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 50.47 vs. TFX: 57.82 )
Ranked among companies with meaningful Shiller PE Ratio only.
TFX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.86  Med: 21.78 Max: 58.12
Current: 57.82
10.86
58.12
Current Ratio 4.72
TFX's Current Ratio is ranked higher than
66% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. TFX: 4.72 )
Ranked among companies with meaningful Current Ratio only.
TFX' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 2.23 Max: 5.2
Current: 4.72
1.46
5.2
Quick Ratio 3.70
TFX's Quick Ratio is ranked higher than
65% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. TFX: 3.70 )
Ranked among companies with meaningful Quick Ratio only.
TFX' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.29 Max: 4.01
Current: 3.7
0.86
4.01
Days Inventory 135.42
TFX's Days Inventory is ranked higher than
53% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. TFX: 135.42 )
Ranked among companies with meaningful Days Inventory only.
TFX' s Days Inventory Range Over the Past 10 Years
Min: 121.53  Med: 140.15 Max: 171.38
Current: 135.42
121.53
171.38
Days Sales Outstanding 54.17
TFX's Days Sales Outstanding is ranked higher than
71% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. TFX: 54.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
TFX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.93  Med: 59.32 Max: 74.92
Current: 54.17
52.93
74.92
Days Payable 32.78
TFX's Days Payable is ranked lower than
77% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. TFX: 32.78 )
Ranked among companies with meaningful Days Payable only.
TFX' s Days Payable Range Over the Past 10 Years
Min: 26.07  Med: 32.72 Max: 42.07
Current: 32.78
26.07
42.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.51
TFX's Dividend Yield % is ranked lower than
76% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 1.38 vs. TFX: 0.51 )
Ranked among companies with meaningful Dividend Yield % only.
TFX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.51  Med: 1.74 Max: 3.48
Current: 0.51
0.51
3.48
Dividend Payout Ratio 0.25
TFX's Dividend Payout Ratio is ranked higher than
71% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 0.36 vs. TFX: 0.25 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TFX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.25  Med: 0.39 Max: 0.62
Current: 0.25
0.25
0.62
Forward Dividend Yield % 0.51
TFX's Forward Dividend Yield % is ranked lower than
80% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. TFX: 0.51 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.51
TFX's 5-Year Yield-on-Cost % is ranked lower than
78% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. TFX: 0.51 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TFX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.51  Med: 1.74 Max: 3.48
Current: 0.51
0.51
3.48
3-Year Average Share Buyback Ratio -2.30
TFX's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. TFX: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TFX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.9  Med: -1.1 Max: 0.8
Current: -2.3
-2.9
0.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.99
TFX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
62% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. TFX: 2.99 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TFX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.47  Med: 1.28 Max: 3.4
Current: 2.99
0.47
3.4
Price-to-Median-PS-Value 3.15
TFX's Price-to-Median-PS-Value is ranked lower than
95% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. TFX: 3.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TFX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 0.55 Max: 3.2
Current: 3.15
0.38
3.2
Earnings Yield (Greenblatt) % 2.61
TFX's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. TFX: 2.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TFX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.2  Med: 4.9 Max: 9.4
Current: 2.61
-3.2
9.4
Forward Rate of Return (Yacktman) % 0.19
TFX's Forward Rate of Return (Yacktman) % is ranked lower than
70% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 6.44 vs. TFX: 0.19 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TFX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.19  Med: 7.5 Max: 19.1
Current: 0.19
0.19
19.1

More Statistics

Revenue (TTM) (Mil) $2,065.13
EPS (TTM) $ 5.47
Beta1.08
Short Percentage of Float2.53%
52-Week Range $142.97 - 269.78
Shares Outstanding (Mil)45.05

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,154 2,425 2,357
EPS ($) 8.23 9.61 10.77
EPS without NRI ($) 8.23 9.61 10.77
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.10%
Dividends per Share ($) 1.33 1.36 1.36

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}